All Posts: clinical trials
-
Investigational Drug Shows Promise in a Clinical Trial for Lung Cancers With ALK Mutations
Early signals from phase 1 of the ALKOVE-1 clinical trial suggest potential benefit from the use of an investigational drug called NVL-655 in people whose non-small cell lung cancer has alterations in a gene called ALK.
Category: News Release
-
ISPY2: A Unique, Flexible Breast Cancer Trial for Modern Times
The ISPY2 breast cancer clinical trial is a unique phase 2 study that offers a broad range of treatment options for patients with locally advanced breast cancer.
Category: GUMC Stories
-
Experimental Therapy Shows Promise in Pancreatic Cancer Clinical Trial
Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda). Immunotherapy drugs alone have not shown to be responsive to pancreatic cancer.
Category: News Release
-
The Aspirin Conundrum: Navigating Negative Results, Age, Aging Dynamics and Equity
A new study examining the role of aspirin in breast cancer treatment reveals critical issues related to health equity and aging that have broad implications for cancer and other disease intervention trials, say researchers from Georgetown University’s Lombardi Comprehensive Cancer Center. They outline their concerns in an editorial accompanying the study’s findings published April 29 in the JAMA.
Category: News Release
-
Georgetown Study Explores THC/CBD Combination to Reduce Dementia-related Agitation at the End of Life
In a first-of-its-kind clinical trial, the Georgetown University Medical Center Memory Disorders Program will study the effects of an oral drug called T2:C100, which is comprised of two components found in marijuana — THC and CBD. The goal of the study is to investigate its potential to decrease agitation experienced by those with dementia at the end of life.
Category: News Release
-
Understanding Immunotherapy Resistance Leads to New Therapeutic Strategies — and Hope
Samir Khleif, MD, an immunologist and professor of oncology at Georgetown Lombardi, is working to understand why some cancers become resistant to immunotherapy, and how that resistance can be overcome.
Category: GUMC Stories
-
New Study Finds Personalized mRNA Vaccine Given with Immunotherapy Reduces Recurrence in High-Risk Melanoma Patients
A new study conducted by an international team of researchers, including clinical investigators at Georgetown Lombardi and John Theurer Cancer Center, demonstrates that a personalized cancer mRNA vaccine combined with immunotherapy reduces recurrence and improves survival for people with advanced melanoma.
Category: News Release
-
Ruesch Symposium Participants Encourage Patients to Consider Clinical Trials
Held by the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, the Ruesch Symposium brings together researchers, clinicians, patients, caregivers, policymakers and advocates for networking and discussion on the latest developments in GI cancer research and treatment.
Category: GUMC Stories
-
The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology
Category: News Release
-
Advanced Melanoma Survival Improves Significantly When Immunotherapy is Given Before Targeted Therapy
Category: News Release